BOSTON, August 25, 2026, 13:15 EDT
- Shares of CRISPR Therapeutics climbed 5.8% to $60.38 as of 12:38:56 EDT.
- The action boosted market value by approximately $319 million.
- Citizens maintained an $80 price target ahead of CTX310 data expected August 28.
- As of June 30, cash and securities totaled $2.36 billion.
Shares of CRISPR Therapeutics AG rose 5.8% on Tuesday, increasing its market capitalisation by roughly $319 million ahead of new CTX310 clinical results.
Shares were last at $60.38 as of 12:38:56 EDT, after earlier climbing to $61.55, the highest level since early August. Trading volume stood at 1.10 million, below the usual daily average of 1.59 million shares.
The trigger is highly specific. CRISPR Therapeutics NASDAQ:CRSP is set to share updated CTX310 results on Friday at the European Society of Cardiology congress.
CTX310 works by editing the ANGPTL3 gene in the liver. The Phase 1 trial is aimed at treating severe triglyceride and cholesterol conditions. Friday’s update will highlight how long the effects last.
Citizens analyst Silvan Tuerkcan on Tuesday maintained a Market Outperform rating. His price target of $80 suggests a 32.5% increase from midday levels. Tuerkcan commented that the treatment has the potential to become “a truly differentiated, one-time therapy.” Citizens note reported by Investing.com
| Analyst | Rating | Target | Upside/downside from $60.38 |
|---|---|---|---|
| Citizens | Market Outperform | $80 | +32.5% |
| Goldman Sachs | Hold | $55 | −8.9% |
| Bank of America | Buy | $82 | +35.8% |
| Morgan Stanley | Hold | $60 | −0.6% |
| Piper Sandler | Buy | $110 | +82.2% |
Investors are buying in advance of the data release. At an $80 share price, the company’s valuation would approach $7.74 billion, around $1.90 billion higher than its capitalization at midday.
CRISPR holds a substantial financial buffer. Cash, equivalents and marketable securities stood at $2.364 billion as of June 30, representing roughly 40% of the company’s midday market capitalization on Tuesday.
The company remains cash flow negative. Revenue for the second quarter totaled $10.2 million, with research expenditures amounting to $67.2 million. Net loss decreased to $91.2 million, compared with $208.5 million previously.
The initial commercial product has established an additional valuation reference. CASGEVY posted $76 million in worldwide revenue for the second quarter, representing a 78% increase from the previous quarter. Vertex Pharmaceuticals Incorporated NASDAQ:VRTX heads commercialization efforts and splits program economics 60-40 with CRISPR.
CTX310 is significant as it has the potential to expand that foundation. In contrast to CASGEVY, this treatment modifies cells within patients themselves. Sustained decreases in lipid levels would enhance the pipeline’s value outside of rare blood disorders.
The late-breaking session on Friday is scheduled to start at 16:30 CEST in Munich. Investors are set to evaluate durability in relation to prior safety and biomarker findings. Individual patient data is expected to be more important than the main result.
Risks: CTX310 is still in its early stages. Limited sample sizes may exaggerate effectiveness and overlook rare safety issues. If durability data is disappointing, Tuesday’s gains could quickly fade.
